Haemonetics Share Price (NYSE: HAE)

$56.34

▲

2.36

(4.37%)

Last updated on August 23, 2025 at 1:29 AM IST

$₹

Check the interactive Haemonetics Stock chart to analyse performance

Haemonetics stock performance

as on August 23, 2025 at 1:29 AM IST

Today's Low:$54.25
Today's High:$56.59
$56.34
3.71%
Downside
Day's Volatility :4.14%
Upside
0.44%
52 Weeks Low:$50.68
52 Weeks High:$94.99
$56.34
10.05%
Downside
52 Weeks Volatility :46.64%
Upside
40.69%

Haemonetics Stock Returns

Period	Haemonetics Corp	Sector (Health Care)	Index (Russel 2000)
3 Months	-17.14%	5.1%	0.0%
6 Months	-14.54%	-6.4%	0.0%
1 Year	-26.12%	-11.8%	0.0%
3 Years	-26.73%	5.9%	-7.8%

Haemonetics Corp Key Stats

Check Haemonetics key stats like market cap, P/E ratio, EPS, Dividend Yield, and more.

Previous Close	$53.98
Open	$54.295
Today's High	$56.59
Today's Low	$54.25
Market Capitalization	$2.6B
Today's Volume	$1.1M
52 Week High	$94.985
52 Week Low	$50.68
Revenue TTM	$1.3B
EBITDA	$369.6M
Earnings Per Share (EPS)	$3.27
PE Ratio	16.51
Profit Margin	12.14%
Quarterly Earnings Growth YOY	-0.05%
Return On Equity TTM	18.27%

Stock Returns calculator for Haemonetics Stock including INR - Dollar returns

The Haemonetics stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Return is the profit earned when the US dollar rises in value compared to the Indian rupee.

Investment Value

₹1,00,000

Haemonetics investment value today

Current value as on today

₹78,204

Returns

₹21,796

(-21.8%)

Returns from Haemonetics Stock

₹26,111 (-26.11%)

Dollar Returns*

₹4,316 (+4.32%)

Indian investors sentiment towards Haemonetics Stock

900%

Period: Jul 23, 2025 to Aug 22, 2025. Change in 30 Days versus previous period

Search interest for Haemonetics Stock from India on INDmoney has increased by 900% in the last 30 days, reflecting an upward trend in search activity.

Global Institutional Holdings in Haemonetics Corp

Name
Holdings %
Name
Holdings %
BlackRock Inc
13.20%
Vanguard Group Inc
10.29%
Neuberger Berman Group LLC
9.03%
Wellington Management Company LLP
4.46%
State Street Corp
3.98%
T. Rowe Price Investment Management,Inc.
3.31%

Analyst Recommendation on Haemonetics Stock

Rating

Trend

Buy

72%Buy

27%Hold

0%Sell

Based on 11 Wall street analysts offering stock ratings for Haemonetics(by analysts ranked 0 to 5 stars)

Haemonetics Share Price Target

What analysts predicted

Upside of 39.57%

Target:

$78.64

Current:

$56.34

Haemonetics share price target is $78.64, a slight Upside of 39.57% compared to current price of $56.34 as per analysts' prediction.

Haemonetics Stock Insights

Price Movement
In the last 1 month, HAE stock has moved down by -27.5%
Decreasing Revenue
Revenue is down for the last 3 quarters, 348.54M → 321.39M (in $), with an average decrease of 4.0% per quarter
Decreasing Net Profit
Netprofit is down for the last 2 quarters, 57.98M → 34.03M (in $), with an average decrease of 41.3% per quarter
HAE vs BSX (1 yr)
In the last 1 year, Boston Scientific Corp. has given 32.9% return, outperforming this stock by 62.1%
HAE vs BSX (3 yr)
In the last 3 years, Boston Scientific Corp. has given 157.5% return, outperforming this stock by 186.0%
Price to Sales
ForHAE every $1 of sales, investors are willing to pay $2.1, whereas for Boston Scientific Corp., the investors are paying $8.5 for every $1 of sales.

Haemonetics Corp Financials

Revenue

Profit

Cash Flow

Annually

Quarterly

FY20

FY21

FY22

FY23

FY24

FY25

	FY20	Y/Y Change
Revenue	$988.5M	↑ 2.16%
Net Income	$76.5M	↑ 39.09%
Net Profit Margin	7.74%	↑ 2.05%

	FY21	Y/Y Change
Revenue	$870.5M	↓ 11.94%
Net Income	$79.5M	↑ 3.85%
Net Profit Margin	9.13%	↑ 1.39%

	FY22	Y/Y Change
Revenue	$993.2M	↑ 14.1%
Net Income	$43.4M	↓ 45.42%
Net Profit Margin	4.37%	↓ 4.76%

	FY23	Y/Y Change
Revenue	$1.2B	↑ 17.67%
Net Income	$115.4M	↑ 166.05%
Net Profit Margin	9.87%	↑ 5.5%

	FY24	Y/Y Change
Revenue	$1.3B	↑ 12.01%
Net Income	$117.6M	↑ 1.87%
Net Profit Margin	8.98%	↓ 0.89%

	FY25	Y/Y Change
Revenue	$1.4B	↑ 3.95%
Net Income	$167.7M	↑ 42.64%
Net Profit Margin	12.32%	↑ 3.34%

Q1 FY24

Q2 FY24

Q3 FY24

Q4 FY24

Q1 FY25

Q2 FY25

	Q1 FY24	Q/Q Change
Revenue	$343.3M	↑ 2.09%
Net Income	$20.4M	↓ 34.81%
Net Profit Margin	5.93%	↓ 3.36%

	Q2 FY24	Q/Q Change
Revenue	$336.2M	↓ 2.07%
Net Income	$38.4M	↑ 88.41%
Net Profit Margin	11.41%	↑ 5.48%

	Q3 FY24	Q/Q Change
Revenue	$345.5M	↑ 2.78%
Net Income	$33.8M	↓ 11.84%
Net Profit Margin	9.79%	↓ 1.62%

	Q4 FY24	Q/Q Change
Revenue	$348.5M	↑ 0.88%
Net Income	$37.5M	↑ 10.83%
Net Profit Margin	10.76%	↑ 0.97%

	Q1 FY25	Q/Q Change
Revenue	$330.6M	↓ 5.15%
Net Income	$58.0M	↑ 54.64%
Net Profit Margin	17.54%	↑ 6.78%

	Q2 FY25	Q/Q Change
Revenue	$321.4M	↓ 2.78%
Net Income	$34.0M	↓ 41.31%
Net Profit Margin	10.59%	↓ 6.95%

FY20

FY21

FY22

FY23

FY24

FY25

	FY20	Y/Y Change
Profit	$484.5M	↑ 16.04%

	FY21	Y/Y Change
Profit	$397.8M	↓ 17.89%

	FY22	Y/Y Change
Profit	$505.5M	↑ 27.06%

	FY23	Y/Y Change
Profit	$615.1M	↑ 21.68%

	FY24	Y/Y Change
Profit	$691.5M	↑ 12.43%

	FY25	Y/Y Change
Profit	$749.0M	↑ 8.3%

Q1 FY24

Q2 FY24

Q3 FY24

Q4 FY24

Q1 FY25

Q2 FY25

	Q1 FY24	Q/Q Change
Profit	$171.6M	↓ 3.52%

	Q2 FY24	Q/Q Change
Profit	$174.9M	↑ 1.94%

	Q3 FY24	Q/Q Change
Profit	$187.4M	↑ 7.15%

	Q4 FY24	Q/Q Change
Profit	$193.5M	↑ 3.26%

	Q1 FY25	Q/Q Change
Profit	$193.1M	↓ 0.26%

	Q2 FY25	Q/Q Change
Profit	$180.5M	↓ 6.52%

FY20

FY21

FY22

FY23

FY24

FY25

	FY20	Y/Y Change
Operating Cash Flow	$158.2M	↓ 0.67%
Investing Cash Flow	$-57.2M	↓ 50.77%
Financing Cash Flow	$-131.2M	↑ 159.16%

	FY21	Y/Y Change
Operating Cash Flow	$108.8M	↓ 31.23%
Investing Cash Flow	$-425.4M	↑ 644.09%
Financing Cash Flow	$367.5M	↓ 380.05%

	FY22	Y/Y Change
Operating Cash Flow	$172.3M	↑ 58.32%
Investing Cash Flow	$-86.3M	↓ 79.7%
Financing Cash Flow	$-15.7M	↓ 104.29%

	FY23	Y/Y Change
Operating Cash Flow	$273.1M	↑ 58.51%
Investing Cash Flow	$-143.8M	↑ 66.53%
Financing Cash Flow	$-100.4M	↑ 537.27%

	FY24	Y/Y Change
Operating Cash Flow	$181.8M	↓ 33.44%
Investing Cash Flow	$-322.4M	↑ 124.21%
Financing Cash Flow	$38.2M	↓ 138.02%

	FY25	Y/Y Change
Operating Cash Flow	$181.7M	↓ 0.01%
Investing Cash Flow	$-161.9M	↓ 49.78%
Financing Cash Flow	$108.8M	↑ 185.18%

Q1 FY24

Q2 FY24

Q3 FY24

Q4 FY24

Q1 FY25

Q2 FY25

	Q1 FY24	Q/Q Change
Operating Cash Flow	$64.1M	↓ 11966.85%
Investing Cash Flow	$-13.1M	↓ 95.15%
Financing Cash Flow	$-63.5M	↓ 158.03%

	Q2 FY24	Q/Q Change
Operating Cash Flow	$-27.4M	↓ 142.79%
Investing Cash Flow	$-139.2M	↑ 966.15%
Financing Cash Flow	$333.7M	↓ 625.48%

	Q3 FY24	Q/Q Change
Operating Cash Flow	$48.8M	↓ 278.05%
Investing Cash Flow	$-23.4M	↓ 83.21%
Financing Cash Flow	$-74.8M	↓ 122.42%

	Q4 FY24	Q/Q Change
Operating Cash Flow	$43.8M	↓ 10.36%
Investing Cash Flow	$-17.4M	↓ 25.66%
Financing Cash Flow	$1.4M	↓ 101.84%

	Q1 FY25	Q/Q Change
Operating Cash Flow	$116.6M	↑ 166.32%
Investing Cash Flow	$18.0M	↓ 203.85%
Financing Cash Flow	$-151.5M	↓ 11074.64%

	Q2 FY25	Q/Q Change
Operating Cash Flow	$17.4M	↓ 85.08%
Investing Cash Flow	$-33.0M	↓ 282.93%
Financing Cash Flow	$-2.4M	↓ 98.39%

Haemonetics Technicals Summary

Sell

Neutral

Buy

Haemonetics is currently in a neutral trading position according to technical analysis indicators.

Haemonetics Corp Vs Peers

Returns

Ratio's

Overview

Company Name	1 Month	6 Month	1 Year	3 Years	5 Years
Haemonetics Corp	-24.14%	-14.54%	-26.12%	-26.73%	-37.18%
Medtronic Plc	-1.34%	2.83%	4.95%	3.85%	-7.4%
Edwards Lifesciences Corp.	7.15%	12.37%	15.35%	-13.9%	3.87%
Boston Scientific Corp.	-0.95%	1.69%	34.08%	157.96%	172.6%
Stryker Corporation	-3.01%	1.6%	11.55%	85.46%	108.86%
Abbott Laboratories	5.09%	-1.77%	17.63%	25.72%	30.74%

Company Name	P/E Ratio	P/B Ratio	PEG Ratio	EPS	ROE	ROA	Div Yield	BVPS
Haemonetics Corp	16.51	16.51	0.93	4.54	0.18	0.07	NA	18.32
Medtronic Plc	25.17	25.17	2.19	5.46	0.1	0.04	0.03	37.46
Edwards Lifesciences Corp.	33.96	33.96	4.86	2.5	0.16	0.08	NA	17.94
Boston Scientific Corp.	63.13	63.13	1.84	2.98	0.12	0.05	NA	15.14
Stryker Corporation	51.83	51.83	2.23	13.49	0.14	0.08	0.01	55.43
Abbott Laboratories	16.56	16.56	4.17	5.14	0.31	0.07	0.02	29.05

Company Name	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin
Haemonetics Corp	Buy	$2.6B	-37.18%	16.51	12.14%
Medtronic Plc	Buy	$116.7B	-7.4%	25.17	13.63%
Edwards Lifesciences Corp.	Buy	$47.6B	3.87%	33.96	72.96%
Boston Scientific Corp.	Buy	$157.1B	172.6%	63.13	13.55%
Stryker Corporation	Buy	$149.8B	108.86%	51.83	12.25%
Abbott Laboratories	Buy	$229.7B	30.74%	16.56	32.43%

About Haemonetics Corp

Haemonetics Corporation, a medical technology company, provides a suite of hospital technologies solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions, including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 tools. It also provides treatment in electrophysiology, critical care, neurocritical care, trauma, burn surgery, spine surgery, and cancer surgery; SavvyWire, a sensor-guided 3-in-1 guidewire for TAVR procedures; and OptoWire, a pressure guidewire that measures fractional flow reserve and diastolic pressure ratio, as well as fiber optic sensor solutions used in medical devices and other critical industrial applications. In addition, the company offers hospital products comprising TEG and HAS hemostasis analyzer systems that provide a comprehensive assessment of a patient's overall hemostasis; and TEG Manager software, which connects various TEG analyzers throughout the hospital, providing clinicians remote access to active and historical test results that inform treatment decisions. Further, it provides Cell Saver Elite +, an autologous blood recovery system for cardiovascular, orthopedic, trauma, transplant, vascular, obstetrical, and gynecological surgeries; and VASCADE closure products comprising VASCADE 5F, VASCADE 6/7F, VASCADE MVP XL, and VASCADE MVP, a technology platform which offers catheter-based delivery system and leverages the natural clot-inducing properties of collagen. The company sells its products through direct sales force, independent distributors, clinical specialists, and sales representatives. Haemonetics Corporation was founded in 1971 and is headquartered in Boston, Massachusetts.

Organization	Haemonetics
Employees	3023
CEO	Mr. Christopher A. Simon
Industry	Health Technology

Key Management of Haemonetics Corp

Name	Title
Mr. Christopher A. Simon	CEO, President & Director
Mr. James C. D'Arecca CPA	CFO, Executive VP & Financial Officer
Ms. Michelle L. Basil Esq., J.D.	Executive VP, General Counsel & Secretary
Mr. Roy Galvin	Executive VP & Chief Commercial Officer
Mr. Frank W. Chan Ph.D.	Executive VP & COO
Ms. Farris Maryanne Maunsell	VP, Chief Accounting Officer & Principal Accounting Officer
Ms. Olga Guyette	Senior Director of Investor Relations
Mr. Rajeev Varma	Senior Vice President of Strategy & Corporate Development
Ms. Laurie A. Miller	Senior VP & Chief Human Resources Officer
Dr. Jan Hartmann M.D.	Senior VP & Chief Medical Officer

Important FAQs about investing in HAE Stock from India :

What is Haemonetics share price today?

Haemonetics share price today is $56.34 as on August 23, 2025 at 1:29 AM IST at the close of the market. Haemonetics share today touched a day high of $56.59 and a low of $54.25.

What is the 52 week high and 52 week low for Haemonetics share?

Haemonetics share touched a 52 week high of $94.99 and a 52 week low of $50.68. Haemonetics stock price today i.e. August 23, 2025 at 1:29 AM IST is closed at $56.34, lower by 40.69% versus the 52 week high.

How to invest in Haemonetics Stock (HAE) from India?

Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
Step 2: Search for Haemonetics on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Haemonetics Shares that will get you 0.0266 shares as per Haemonetics share price of $56.34 per share as on August 23, 2025 at 1:29 AM IST.

What is the minimum amount required to buy Haemonetics Stock (HAE) from India?

Indian investors can start investing in Haemonetics (HAE) shares with as little as ₹87.521 or $1 (as of August 23, 2025) using the INDmoney app.
For example: If you want to invest $10 or ₹875.21 in Haemonetics stock (as per the Rupee-Dollar exchange rate as on August 23, 2025). Based on Haemonetics share’s latest price of $56.34 as on August 23, 2025 at 1:29 AM IST, you will get 0.1775 shares of Haemonetics. Learn more about fractional shares .

What are the returns that Haemonetics has given to Indian investors in the last 5 years?

Haemonetics stock has given -37.18% share price returns and 18.0% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your US Stock Investments?